FDA Advisory Meetings（10月５日）
公開日時 2009/10/13 04:00
| Topic |
Advisory Committee |
Date |
| Neuromed's Exalgo (modified-release hydromorphone) for moderate to severe pain in opioid-tolerant patients |
Anesthetic Life Support Drugs and Drug Safety and Risk Management |
Sept. 23 |
| Discussion of new data for Purdue's Oxycontin (oxycodone hydrochloride controlled-release) tablets for moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time |
Anesthetic Life Support Drugs and Drug Safety and Risk Management |
Sept. 24 |
| Schering Plough's PegIntron (peginterferon alfa-2b) as an adjuvant to surgery for metastatic melanoma, and GlaxoSmithKline's Armala (pazopanib) for advanced renal cell carcinoma |
Oncologic Drugs |
Oct. 5 |
| ApoPharma's Ferriprox (deferiprone) as an iron chelating agent to treat iron overload or build-up in patients with transfusion-dependent thalassemia or other transfusion-dependent anemias |
Oncologic Drugs |
Oct. 6 |
| Pfizer's Selzentry (maraviroc) for supplemental indication to treat antiretroviral-naïve patients with chemokine (c-c motif) receptor 5 (CCR5) tropic human immunodeficiency virus |
Antiviral Drugs |
Oct. 8 |
| Fibrocell Technologies' Isolagen Therapy, BLA 125348, for moderate to severe nasolabial fold wrinkles |
Cellular, Tissue and Gene Therapies |
Oct. 9 |
| Acorda Therapeutics' Amaya (fampridine-SR) to improve walking ability in multiple sclerosis patients |
Peripheral and Central Nervous System Drugs |
Oct. 14 |
| Discussion of updated susceptibility test information in systemic antibacterial drug product labeling |
Anti-Infective Drugs |
Oct. 26 |
| Human Genome Sciences' raxibacumab injection to treat inhalational anthrax disease |
Anti-Infective Drugs |
Oct. 27 |
| Committee will hear updates on several topics including the 2009 A/H1N1 pandemic and the impact on blood safety and availability |
Blood Products |
Nov. 16-17 |
| Genentech/Novartis' Xolair (omalizumab) for moderate to severe persistent allergic asthma in patients between six and 11 years of age |
Pulmonary-Allergy Drugs |
Nov. 18 |
| Boehringer Ingelheim's Spiriva HandiHaler (tiotropium inhalation powder) for the reduction in exacerbations in patients with chronic obstructive pulmonary disease |
Pulmonary-Allergy Drugs |
Nov. 19 |
| Pharmaxis' Aridol (mannitol bronchial challenge test) to assess bronchial hyperresponsiveness to help diagnose asthma |
Pulmonary-Allergy Drugs |
Nov. 20 |
（The Pink Sheet 10月５日号より） FDAと米国製薬企業の情報満載 “The Pink Sheet”はこちらから